Chapter 3 Cerebrovascular and Cardiovascular Pathology in Alzheimer's Disease

作者: Jack C. de la Torre

DOI: 10.1016/S0074-7742(09)00403-6

关键词: NeuroimagingCardiovascular pathologyDiseaseNeuroscienceWindow of opportunityCerebral hypoperfusionDementiaPsychologyVascular Disorder

摘要: Presently, compelling evidence indicates that Alzheimer's disease (AD) is a vascular disorder with neurodegenerative consequences and should be treated as such. A substantial body of including epidemiological, pharmacotherapeutic, neuroimaging studies support the concept AD or vasocognopathy initiates brain hypoperfusion, creating neuronal energy crisis. The crisis provokes cellular molecular changes characterize this dementia. In brief review, many vascular‐related risk factors to some are preventable amenable treatment discussed. Considerable human data now point in new direction for guiding future research into AD. This open window opportunity decisive management devastating disorder.

参考文章(32)
J.C. de la Torre, T. Mussivan, Can disturbed brain microcirculation cause Alzheimer’s disease? Neurological Research. ,vol. 15, pp. 146- 153 ,(1993) , 10.1080/01616412.1993.11740127
Jack C. de la Torre, Alzheimer's disease prevalence can be lowered with non-invasive testing. Journal of Alzheimer's Disease. ,vol. 14, pp. 353- 359 ,(2008) , 10.3233/JAD-2008-14310
K. Jones, B. L. Holman, J. A. Becker, P. A. Spiers, A. Satlin, M. S. Albert, K. A. Johnson, Preclinical prediction of Alzheimer's disease using SPECT Neurology. ,vol. 50, pp. 1563- 1571 ,(1998) , 10.1212/WNL.50.6.1563
Hedda Agüero-Torres, Miia Kivipelto, Eva von Strauss, Rethinking the dementia diagnoses in a population-based study: what is Alzheimer's disease and what is vascular dementia?. A study from the kungsholmen project. Dementia and Geriatric Cognitive Disorders. ,vol. 22, pp. 244- 249 ,(2006) , 10.1159/000094973
I J Martins, E Hone, J K Foster, S I Sünram-Lea, A Gnjec, S J Fuller, D Nolan, S E Gandy, R N Martins, Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Molecular Psychiatry. ,vol. 11, pp. 721- 736 ,(2006) , 10.1038/SJ.MP.4001854
Monique M.B Breteler, Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiology of Aging. ,vol. 21, pp. 153- 160 ,(2000) , 10.1016/S0197-4580(99)00110-4
Jack C. de La Torre, Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurological Research. ,vol. 26, pp. 517- 524 ,(2004) , 10.1179/016164104225016254
D. Larry Sparks, Marwan N. Sabbagh, Donald J. Connor, Jean Lopez, Lenore J. Launer, Patrick Browne, Dawn Wasser, Sherry Johnson-Traver, Jeff Lochhead, Chuck Ziolwolski, Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. JAMA Neurology. ,vol. 62, pp. 753- 757 ,(2005) , 10.1001/ARCHNEUR.62.5.753